Post

one more Question

Girija Muralidhar, Ph.D, Director of Vaccines Program, Virogenics Inc.
Alpha-Synuclein Aggregation, PARK1/4 (SNCA/Alpha-Synuclein), Targeting Alpha-Synuclein
Response to Discussion:
What species of alpha-synuclein should be targeted for development of PD therapies?
View all 5 responses to this Discussion

Hello,

I have heard about the following study, which form of alpha-synuclein was used and is there any more information on the outcomes of this study?

" Elan and collaborators at the University of California, San Diego, USA, have reported promising of a vaccine approach to treating Parkinson's and other Lewy Body diseases, in mice.

Rodents were injected with the abnormal form of alpha-synuclein that aggregates in the brains of LB patients and..".

Reply
Responses: